↓ Skip to main content

Inflammation-Associated Depression: Evidence, Mechanisms and Implications

Overview of attention for book
Cover of 'Inflammation-Associated Depression: Evidence, Mechanisms and Implications'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 2 Evidence for Inflammation-Associated Depression
  3. Altmetric Badge
    Chapter 5 Suicidality and Activation of the Kynurenine Pathway of Tryptophan Metabolism.
  4. Altmetric Badge
    Chapter 6 Role of the Kynurenine Metabolism Pathway in Inflammation-Induced Depression: Preclinical Approaches.
  5. Altmetric Badge
    Chapter 7 Depression in Autoimmune Diseases.
  6. Altmetric Badge
    Chapter 12 Role of Kynurenine Metabolism Pathway Activation in Major Depressive Disorders.
  7. Altmetric Badge
    Chapter 13 The Role of Dopamine in Inflammation-Associated Depression: Mechanisms and Therapeutic Implications
  8. Altmetric Badge
    Chapter 14 Role of Inflammation in the Development of Neuropsychiatric Symptom Domains: Evidence and Mechanisms.
  9. Altmetric Badge
    Chapter 19 Are Non-steroidal Anti-Inflammatory Drugs Clinically Suitable for the Treatment of Symptoms in Depression-Associated Inflammation?
  10. Altmetric Badge
    Chapter 23 Mechanisms of Inflammation-Associated Depression: Immune Influences on Tryptophan and Phenylalanine Metabolisms.
  11. Altmetric Badge
    Chapter 25 Stress-Induced Microglia Activation and Monocyte Trafficking to the Brain Underlie the Development of Anxiety and Depression.
  12. Altmetric Badge
    Chapter 26 The Promise and Limitations of Anti-Inflammatory Agents for the Treatment of Major Depressive Disorder
  13. Altmetric Badge
    Chapter 28 Inflammation-Associated Co-morbidity Between Depression and Cardiovascular Disease
  14. Altmetric Badge
    Chapter 30 Brain Structures Implicated in Inflammation-Associated Depression
  15. Altmetric Badge
    Chapter 31 Does Diet Matter? The Use of Polyunsaturated Fatty Acids (PUFAs) and Other Dietary Supplements in Inflammation-Associated Depression.
  16. Altmetric Badge
    Chapter 37 Immune-to-Brain Communication Pathways in Inflammation-Associated Sickness and Depression
  17. Altmetric Badge
    Chapter 40 Inflammation Effects on Brain Glutamate in Depression: Mechanistic Considerations and Treatment Implications.
  18. Altmetric Badge
    Chapter 43 Role of Neuro-Immunological Factors in the Pathophysiology of Mood Disorders: Implications for Novel Therapeutics for Treatment Resistant Depression.
Attention for Chapter 19: Are Non-steroidal Anti-Inflammatory Drugs Clinically Suitable for the Treatment of Symptoms in Depression-Associated Inflammation?
Altmetric Badge

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
43 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Are Non-steroidal Anti-Inflammatory Drugs Clinically Suitable for the Treatment of Symptoms in Depression-Associated Inflammation?
Chapter number 19
Book title
Inflammation-Associated Depression: Evidence, Mechanisms and Implications
Published in
Current topics in behavioral neurosciences, July 2016
DOI 10.1007/7854_2016_19
Pubmed ID
Book ISBNs
978-3-31-951151-1, 978-3-31-951152-8
Authors

Baune, Bernhard T, Bernhard T. Baune, Baune, Bernhard T.

Editors

Robert Dantzer, Lucile Capuron

Abstract

The aetiology and pathophysiology of depression have long been associated with inflammation, at least in a proportion of patients. Altered cytokine activity in the periphery and in the brain has brought support to a concept of depression-associated inflammation. However, these immunological changes - and inflammation in particular - in depression have only been recently targeted for treatment. Non-steroidal anti-inflammatory drugs (NSAIDs) have been proposed to be of clinical use in the treatment of depression either as monotherapy or as adjuncts in combination with antidepressants. Specifically, selective cyclooxygenase (COX)-2 and non-selective COX inhibitor NSAIDs as adjuncts or monotherapy have been trialled clinically. A limited body of clinical research has been conducted with mixed results so far. Although meta-analyses appear to support the use of NSAIDs in acute depression, the overall effect is mainly biased by the effects of celecoxib for which the best evidence exists to date. Efficacy data of non-selective COX inhibitor NSAIDs on depressive symptoms is limited and out of six studies, only a retrospective analysis shows positive results for non-selective COX inhibitor. Clinical data on aspirin, an irreversible inhibitor of both COX-1 and COX-2, are mainly experimental and hypothetical at this stage, but may be promising in depressed patients with concomitant inflammatory conditions. The main problematic factor is that current evidence rests on trials in acute depression. Because of the dynamic nature of depression, it is important exploring if NSAIDs and other anti-inflammatory treatments may have a preventive role in early stages of depression and for relapse prevention. The possible impact of anti-inflammatory treatments on immune changes in different phases of depression warrants caution for a wide and preventive use of anti-inflammatory agents in depression-associated inflammation.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 43 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 10 23%
Student > Master 8 19%
Student > Ph. D. Student 7 16%
Researcher 4 9%
Other 2 5%
Other 7 16%
Unknown 5 12%
Readers by discipline Count As %
Neuroscience 8 19%
Psychology 8 19%
Medicine and Dentistry 8 19%
Nursing and Health Professions 3 7%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Other 7 16%
Unknown 6 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2017.
All research outputs
#12,239,146
of 15,402,399 outputs
Outputs from Current topics in behavioral neurosciences
#260
of 357 outputs
Outputs of similar age
#183,932
of 261,326 outputs
Outputs of similar age from Current topics in behavioral neurosciences
#8
of 10 outputs
Altmetric has tracked 15,402,399 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 357 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 14th percentile – i.e., 14% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 261,326 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.